Reports Q2 revenues of $21M, consensus $21.48M. Ron Zwanziger, Chairman and CEO of LumiraDx, stated, “The submission of our first 510(k) application to the FDA for our COVID Ultra test represents a significant milestone in our ability to deliver on product expansion into the U.S. and could pave the way for additional submissions of other high performing assays on our Platform, many of which are already available in Europe and elsewhere and others which are in late stages of development. In addition, we are seeing revenues from our non-COVID products continue to grow, with the second quarter marking our highest quarter to date for non-COVID revenues. As we continue to innovate and expand our portfolio, we remain dedicated to transforming healthcare delivery worldwide.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LMDX:
- LumiraDx Reports Second Quarter 2023 Results
- LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
- LMDX Upcoming Earnings Report: What to Expect?
- LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
- LumiraDx signs commercial distribution agreement with Axon Lab